This study is to provide access for patients who are receiving treatment with dabrafenib
and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs
or a former GSK-sponsored study who have fulfilled the requirements for the primary
objective, and who are judged by the investigator as benefiting from continued treatment in
the parent study as judged by the Investigator at the completion of the parent study.